DLBCL

During a Targeted Oncology™ Case-Based Roundtable™ event, Gilles Salles, MD, discussed when to use CAR T-cell therapy in the second-line setting for patients with relapsed/refractory diffuse large B-cell lymphoma and the outcomes of trials of these agents. This is the first of 2 articles based on this event.

During a Targeted Oncology™ Case-Based Roundtable™ event, Bruce D. Cheson, MD, discussed adverse event management and dosing strategies for patients receiving tafasitamab and lenalidomide for diffuse large B-cell lymphoma.

Findings from the phase 2 DALY II USA trial showed that the 28-day objective response rate was 78% with freshly administered zamtocabtagene autoleucel, exceeding the prespecified efficacy threshold for interim analysis.

Early results announced from the VITALIZE study show efficacy and safety of maveropepimut-S plus pembrolizumab and low-dose, intermittent cyclophosphamide for patients with relapsed/refractory diffuse large B-cell lymphoma.

During a Targeted Oncology case-based roundtable event, Christopher R. Flowers, MD, MS, discussed the choice of bridging therapy for a patient with relapsed/refractory diffuse large B-cell lymphoma who may receive CAR (chimeric antigen receptor) T-cell therapy. This is the second of 2 articles based on this event.

During a Targeted Oncology case-based roundtable event, Christopher R. Flowers, MD, MS, discussed with participants their experiences referring patients for chimeric antigen receptor T-cell therapy and using bridging therapy. This is the first of 2 articles based on this event.

The combination of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone is moving into the frontline setting for patients with diffuse large B-cell lymphoma.

During a Targeted Oncology case-based roundtable event, Matthew Matasar, MD, MS, discussed the case of a patient with diffuse large B-cell lymphoma who relapsed 18 months following frontline combination therapy.

During a Targeted Oncology case-based roundtable event, Tycel Phillips, MD, discussed available therapies for a patient with relapsed/refractory diffuse large B-cell lymphoma including CAR T-cell therapy and combination systemic therapies.

Adaptive Biotechnologies announced the launch of its clonoSEQ ctDNA-based MRD assay for patients with diffuse large B-cell lymphoma.

During a Targeted Oncology case-based roundtable event, Sabarish Ayyappan, MD, discussed with participants which therapy would be appropriate for an older patient with relapsed/refractory diffuse large B-cell lymphoma.

During a Targeted Oncology case-based roundtable event, Jason Westin, MD, discussed recent clinical trial data for patients with relapsed/refractory diffuse B-cell lymphoma.

During a Targeted Oncology case-based roundtable event, Pallawi Torka, MD, discussed with participants the use of novel therapies for patients with diffuse large B-cell lymphoma.

During a case-based rountable event, Jasmine Zain, MD of City of Hope, discussed the case of a 79-year-old patients with relapsed or refractory diffuse large B-cell lymphoma.

Updated results from the L-MIND trial show continued efficacy and safety data for the combination of tafasitamab and lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.

Results from the POLARIX clinical trial support the use of polatuzumab vedotin plus rituximab as frontline treatment for diffuse large B-cell lymphoma.

Ian W. Flinn, MD, PhD, discusses what factors go into his decision to use polatuzumab plus bendamustine and rituximab in certain patients with relapsed/refractory diffuse large B-cell lymphoma.

During a case-based roundtable event, Javier L. Munoz, MD, MBA, discussed data supporting the use of newer therapies for patients with relapsed/refractory diffuse large B-cell lymphoma.

A presentation at ESMO 2022 explains the use of circulating tumor DNA as a tool which can predict outcomes for patients with diffuse large B-cell lymphoma.

The combination of orelabrutinib plus the R-CHOP regimen revealed a positive overall response rate of 86.4% when given to patients with non-germinal center B cell-like diffuse large B-cell lymphoma.

During a Targeted Oncology case-based roundtable event, Pallawi Torka, MD, discussed with participants when to consider a patient for chimeric antigen receptor T-cell therapy and what alternative treatments to use for a patient with relapsed/refractory diffuse large B-cell lymphoma.

Ian W. Flinn, MD, PhD, discusses his experience using the combination of polatuzumab vedotin-piiq plus bendamustine and rituximab for patients with relapsed/refractory diffuse large B-cell lymphoma.

In a study, a correlation between frailty status and death at 1 year was identified in patients with diffuse large B-cell lymphoma.

Ian Flinn, MD, PhD, describes some of the important unmet needs of DLBCL, particularly in R/R DLBCL, and shares his hopes for the future of treatment.

An oncologist shares which treatment regimen he would recommend next for this patient with DLBCL who experienced two disease relapses and reflects on how CD19- and CD79b-targeted therapies have impacted patient outcomes in the field.

Dr Ian Flinn explains the available treatment options for patients with DLBCL who experience 2 or more relapses, and the situations in which he would use each regimen.

An expert provides his perspective on the first- and second-line treatment approaches in the patient case and comments on the patient’s likely prognosis.

Ian Flinn, MD, PhD, presents the case of a 68-year-old man with diffuse large B-cell lymphoma (DLBCL) and 2 relapses after complete disease remission.

A high overall response rate was demonstrated with epcoritamab treatment in patients with diffuse large B-cell lymphoma, according to results from the phase 1/2 EPCORE NHL-2 trial.